Ars Pharmaceuticals Inc (SPRY)

$13.35 +0.06 (0.45%)
Market Cap 1.32B
Revenue (ttm) 89.15M
Net Income (ttm) 8.00M
EPS (ttm) N/A
PE Ratio 168.63
Forward PE N/A
Profit Margin 8.97%
Debt to Equity Ratio 0.27
Volume 1,436,100
Avg Vol 1,726,592
Day's Range N/A - N/A
Shares Out 98.21M
Stochastic %K 19%
Beta 0.84
Analysts Strong Sell
Price Target $31.60

Latest News on SPRY

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

May 14, 2025, 7:00 AM EDT - 2 hours ago

ARS Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Progress in U.S. Commercial Launch of neffy® (epinephrine nasal spray)

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

May 7, 2025, 8:00 AM EDT - 7 days ago

ARS Pharmaceuticals' neffy® (epinephrine nasal spray) 1 mg is Now Available in the United States for Type I Allergic Reactions, including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

May 5, 2025, 8:00 AM EDT - 9 days ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

May 2, 2025, 8:00 AM EDT - 12 days ago

ARS Pharmaceuticals Announces Co-Promotion Agreement with Partner and Global Allergy Leader ALK-Abelló A/S to Expand Reach of neffy® (epinephrine nasal spray) to Additional U.S. Pediatricians

ARS Pharmaceuticals Has A Blockbuster Candidate

Apr 30, 2025, 6:51 AM EDT - 14 days ago

ARS Pharmaceuticals Has A Blockbuster Candidate

ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

Mar 20, 2025, 3:31 PM EDT - 7 weeks ago

ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await

ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript

Mar 20, 2025, 1:28 PM EDT - 7 weeks ago

ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 20, 2025, 7:00 AM EDT - 7 weeks ago

ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

Mar 5, 2025, 4:10 PM EST - 2 months ago

ARS Pharmaceuticals Announces FDA Approval of neffy® 1 mg (epinephrine nasal spray) for Type I Allergic Reactions, Including Anaphylaxis, in Pediatric Patients Weighing 15 to < 30 Kilograms

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

Mar 3, 2025, 4:35 PM EST - 2 months ago

ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2024 Financial Results and Participation at Upcoming Conferences

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

Feb 20, 2025, 7:02 PM EST - 2 months ago

ARS Pharmaceuticals Announces OptumRx, Cigna Healthcare and Navitus Health Systems Add neffy® (Epinephrine Nasal Spray) to National Formularies, Further Expanding Coverage for Patients

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

Feb 18, 2025, 8:00 AM EST - 3 months ago

ARS Pharmaceuticals to Showcase Innovation and Present Data on neffy® (epinephrine nasal spray) at 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

Feb 6, 2025, 1:04 AM EST - 3 months ago

ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

Jan 6, 2025, 8:00 AM EST - 4 months ago

ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

Dec 19, 2024, 5:25 PM EST - 5 months ago

ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

Dec 12, 2024, 2:32 PM EST - 5 months ago

ARS Pharmaceuticals Announces Filings for Approval of neffy® in China, Japan and Australia

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

Dec 4, 2024, 8:00 AM EST - 5 months ago

ARS Pharmaceuticals Announces Planned Launch of neffyinSchools Program to Provide Life-Saving Needle Free Epinephrine to Eligible K-12 Schools at No Cost

ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 12:40 PM EST - 6 months ago

ARS Pharmaceuticals, Inc. (SPRY) Q3 2024 Earnings Call Transcript

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

Nov 13, 2024, 6:30 AM EST - 6 months ago

ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

Nov 11, 2024, 7:41 AM EST - 6 months ago

ARS Pharmaceuticals Inks Licensing Pact For Neffy Allergic Reaction Treatment, Analyst Sees Further Stock Upside Despite 200% Surge In 2024

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

Nov 11, 2024, 7:00 AM EST - 6 months ago

ARS Pharmaceuticals Announces Exclusive Agreement with Global Allergy Leader ALK to Commercialize neffy® in Europe, Canada and Other Geographies Outside the United States

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

Nov 9, 2024, 5:30 PM EST - 6 months ago

ALK licenses rights to neffy®, the first approved adrenaline nasal spray for emergency treatment of allergic reactions (anaphylaxis)

ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 4, 2024, 11:00 AM EST - 6 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 6 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 30, 2024, 11:00 AM EDT - 6 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Oct 24, 2024, 8:30 AM EDT - 7 months ago

ARS Pharmaceuticals Showcases Intranasal Epinephrine Data at 2024 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Reach Out To The Schall Law Firm

Oct 23, 2024, 11:00 AM EDT - 7 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Securities Fraud And Affected Investors Are Urged To Reach Out To The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Oct 19, 2024, 11:00 AM EDT - 7 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Oct 17, 2024, 11:00 AM EDT - 7 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Related Infractions

Oct 8, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Encourages Shareholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Securities Related Infractions

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Impacted Investors Are Encouraged To Reach Out To The Schall Law Firm

Oct 5, 2024, 11:00 AM EDT - 7 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Impacted Investors Are Encouraged To Reach Out To The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Assist The Schall Law Firm

Oct 3, 2024, 11:00 AM EDT - 7 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Assist The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Oct 1, 2024, 11:00 AM EDT - 8 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Contact The Schall Law Firm

Sep 29, 2024, 11:00 AM EDT - 8 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Are Invited To Contact The Schall Law Firm

The Schall Law Firm Urges Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Sep 28, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Urges Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors Are Invited To Assist The Schall Law Firm

Sep 27, 2024, 11:00 AM EDT - 8 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Investors Are Invited To Assist The Schall Law Firm

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Sep 24, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Invites Stockholder Participation In An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Should Contact The Schall Law Firm

Sep 23, 2024, 11:00 AM EDT - 8 months ago

ARS Pharmaceuticals, Inc. Is Being Investigated For Possible Securities Fraud And Affected Investors Should Contact The Schall Law Firm

The Schall Law Firm Urges Stockholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

Sep 20, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Urges Stockholders To Join An Inquiry Into ARS Pharmaceuticals Inc For Violating Securities Laws

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And Investors With Losses Should Contact The Schall Law Firm

Sep 19, 2024, 11:00 AM EDT - 8 months ago

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And Investors With Losses Should Contact The Schall Law Firm

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And The Schall Law Firm Wants Investors To Help With An Inquiry

Sep 17, 2024, 11:00 AM EDT - 8 months ago

ARS Pharmaceuticals, Inc. May Have Committed Securities Fraud And The Schall Law Firm Wants Investors To Help With An Inquiry

The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc For Securities Related Infractions And Shareholders Are Invited To Lend A Hand

Sep 16, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc For Securities Related Infractions And Shareholders Are Invited To Lend A Hand

ARS Pharmaceuticals, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Investors To Join An Inquiry

Sep 15, 2024, 11:00 AM EDT - 8 months ago

ARS Pharmaceuticals, Inc. May Have Violated Securities Laws And The Schall Law Firm Urges Investors To Join An Inquiry

The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc's Possible Securities Fraud And Stockholders Are Invited To Play A Part

Sep 14, 2024, 11:00 AM EDT - 8 months ago

The Schall Law Firm Is Looking Into ARS Pharmaceuticals Inc's Possible Securities Fraud And Stockholders Are Invited To Play A Part